BioSpace News Archive

Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on July 29, 2021.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, announced it will report financial results for the second quarter of 2021 after market close on Thursday, August 12, 2021.

Brickell Biotech, Inc. announced the closing of its previously announced public offering of 12,983,871 shares of common stock of the Company, including the full exercise by the underwriter of its option to purchase 1,693,548 shares of common stock, at a price to the public of $0.62 per share, less underwriting discounts and commissions.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2021, after the financial markets close on Thursday, August 5, 2021.

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has completed enrollment in the Phase 2 CATALINA study, which is evaluating the safety and efficacy of intravitreal (IVT) injections of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.

HCW Biologics Inc. (NASDAQ:HCWB) (the “Company”), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the closing of its previously announced underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share for gross proceeds of $56.0 million,

Arena Pharmaceuticals, Inc. announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 45,200 shares of its common stock and 20,235 inducement restricted stock units.

Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Aug. 5, 2021, following the release of its second quarter 2021 financial results.

Acorda Therapeutics, Inc. announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA® 33 mg in Spain.